Literature DB >> 1473414

Ogilvie's syndrome: colonoscopic decompression and analysis of predisposing factors.

A B Jetmore1, A E Timmcke, J B Gathright, T C Hicks, J E Ray, J W Baker.   

Abstract

Forty-eight cases of Ogilvie's syndrome, colonic pseudo-obstruction, presenting between 1983 and 1989 were retrospectively reviewed to assess the results of colonoscopic decompression and to identify potential etiologic factors. Three patients had spontaneous resolution with medical treatment. Forty-five patients required 60 colonoscopic decompressions: 38 (84 percent) were successfully treated using colonoscopy; five (11 percent) required an operation; and two died within 48 hours of colonoscopy from medical causes. No complications or deaths were the result of colonoscopy. Twenty-nine patients (64 percent) were successfully treated with a single colonoscopy. One-third of patients required serial decompressions. Average cecal diameter in patients with successful colonoscopic decompression was 12.4 cm but was larger for patients requiring more than one colonoscopy (13.3 cm) and for those who failed colonoscopic therapy (13.4 cm). The spine or retroperitoneum had been traumatized or manipulated in 52 percent of patients. Patients with Ogilvie's syndrome were being treated with narcotics (56 percent), H-2 blockers (52 percent), phenothiazines (42 percent), calcium-channel blockers (27 percent), steroids (23 percent), tricyclic antidepressants (15 percent), and epidural analgesics (6 percent) at diagnosis. Electrolyte abnormalities included hypocalcemia (63 percent), hyponatremia (38 percent), hypokalemia (29 percent), hypomagnesemia (21 percent), and hypophosphatemia (19 percent). Colonoscopic decompression in Ogilvie's syndrome is safe and effective management. Multiple pharmacologic and metabolic factors, as well as spinal and retroperitoneal trauma, appear to alter autonomic regulation of colonic function, resulting in colonic pseudo-obstruction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1473414     DOI: 10.1007/bf02251964

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  27 in total

1.  Ogilvie's syndrome in the surgical patient: a new therapeutic modality.

Authors:  C R Schermer; J J Hanosh; M Davis; D E Pitcher
Journal:  J Gastrointest Surg       Date:  1999 Mar-Apr       Impact factor: 3.452

Review 2.  Update on acute colonic pseudo-obstruction.

Authors:  E Y Eaker
Journal:  Curr Gastroenterol Rep       Date:  2001-10

3.  Acute Intestinal Pseudo-obstruction.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-08

Review 4.  Acute colonic pseudoobstruction.

Authors:  Michael D Saunders
Journal:  Curr Gastroenterol Rep       Date:  2004-10

5.  Acute pseudo-obstruction of the large bowel with caecal perforation following normal vaginal delivery: a case report.

Authors:  David Cartlidge; Marlon Seenath
Journal:  J Med Case Rep       Date:  2010-04-29

6.  Intestinal pseudo-obstruction: an uncommon condition with heterogeneous etiology and unpredictable outcome.

Authors:  Eugen Florin Georgescu; Ion Vasile; Reanina Ionescu
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

7.  83-year-old woman with abdominal distention and constipation.

Authors:  Mohammad Albaba; Paul Y Takahashi
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

8.  Spontaneous Caecal Perforation Associated with Ogilvie's Syndrome Following Vaginal Delivery - A Case Report.

Authors:  Harish E; Sundeep Vk; Sivasai Krishnaprasad Kola; Dharma Kumar Kg
Journal:  J Clin Diagn Res       Date:  2014-06-20

9.  Acute Colonic Pseudo-Obstruction (Ogilvie's Syndrome).

Authors:  Jan Tack
Journal:  Curr Treat Options Gastroenterol       Date:  2006-07

10.  Fatal acute intestinal pseudoobstruction in mice.

Authors:  Ricardo E Feinstein; Winston E Morris; Anne Halldén Waldemarson; Patricia Hedenqvist; Ronny Lindberg
Journal:  J Am Assoc Lab Anim Sci       Date:  2008-05       Impact factor: 1.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.